BlackRock Investment Management’s Harvard Bioscience HBIO Stock Holding History

BlackRock Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17K	Hold	570	–	–	﹤0.01%	3425
2016 Q3	$15K	Hold	570	–	–	﹤0.01%	3438
2016 Q2	$16K	Sell	570 -12,094	-95%	-$385K	﹤0.01%	3442
2016 Q1	$382K	Buy	12,664 +138	+1%	+$3.91K	﹤0.01%	3000
2015 Q4	$435K	Buy	12,526 +130	+1%	+$4.45K	﹤0.01%	3046
2015 Q3	$469K	Buy	12,396 +916	+8%	+$42.6K	﹤0.01%	3050
2015 Q2	$654K	Buy	11,480 +10,955	+2,087%	+$623K	﹤0.01%	3027
2015 Q1	$31K	Buy	525 +1	+0.2%	+$54	﹤0.01%	3369
2014 Q4	$30K	Hold	524	–	–	﹤0.01%	3388
2014 Q3	$21K	Buy	524 +22	+4%	+$1.01K	﹤0.01%	3404
2014 Q2	$23K	Sell	502 -8,399	-94%	-$353K	﹤0.01%	3368
2014 Q1	$422K	Buy	8,901 +366	+4%	+$16.7K	﹤0.01%	3041
2013 Q4	$401K	Sell	8,535 -3,064	-26%	-$134K	﹤0.01%	3048
2013 Q3	$463K	Buy	11,599 +153	+1%	+$6.02K	﹤0.01%	2966
2013 Q2	$408K	Buy	+11,446	New	+$438K	﹤0.01%	2958

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock Investment Management's HBIO Position: Q4 2016 in Review

BlackRock Investment Management held its Harvard Bioscience (HBIO) position steady in Q4 2016 at 570 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

BlackRock Investment Management first reported a position in HBIO in Q2 2013 and has held it in 15 quarters since. The position peaked at $654K in Q2 2015. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2016.

BlackRock Investment Management held 570 shares of Harvard Bioscience worth $17K as of Q4 2016.
BlackRock Investment Management left its Harvard Bioscience share count unchanged in Q4 2016.
Harvard Bioscience made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3425 holding.
BlackRock Investment Management first reported a position in Harvard Bioscience in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Harvard Bioscience position peaked at $654K in Q2 2015.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.